QTRX
TEM
Another brick in the precision-medicine wall
Tempus AI is adding another puzzle piece to its health-tech empire. The company said it’s collaborating with Lucent Diagnostics, a Quanterix brand, to widen access to a blood-based biomarker panel aimed at improving Alzheimer’s detection.
Why this matters
This isn’t just a science fair project. Tempus plans to build a Tempus Next care gap program around the testing, which means the company is trying to make the workflow stick inside real clinical settings — the kind of thing that can turn a nice headline into recurring business.
The investor read
For you, the big question is whether Tempus can keep stacking partnerships that make its platform harder to ignore. Alzheimer’s is a huge market, and if this collaboration helps push more testing through Tempus’ network, that’s potentially more data, more reach, and more reasons doctors keep coming back.
- More clinical workflow integration = more embedded product
- Alzheimer’s diagnostics is a large, high-stakes market
- Partnerships like this can strengthen Tempus’ AI + diagnostics story
Big picture: Tempus keeps acting less like a single-product company and more like a platform trying to own more of the care journey.